(Q39392894)

11 September 2017

title

Antibody-response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience (English)

1 reference

multicenter clinical trial

11 September 2017

main subject

0 references

1 reference

1 reference

1 reference

2

Kundi M

1 reference

11 September 2017

Rendi-Wagner P

1

1 reference

11 September 2017

Stemberger H

3

1 reference

11 September 2017

Wiedermann G

4

1 reference

11 September 2017

Holzmann H

5

1 reference

11 September 2017

Hofer M

6

1 reference

11 September 2017

Wiesinger K

7

1 reference

11 September 2017

Kollaritsch H

8

1 reference

11 September 2017

language of work or name

English

0 references

publication date

1 February 2001

1 reference

11 September 2017

number of pages

6

1 reference

inferred from page(s)

published in

Vaccine

1 reference

11 September 2017

volume

19

1 reference

11 September 2017

issue

15-16

1 reference

11 September 2017

page(s)

2055-2060

1 reference

Seroepidemiology of hepatitis B virus infection in children: Ten years of mass vaccination in Taiwan

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900410-2

7 January 2021

A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900410-2

7 January 2021

Multicentre dose range study of a yeast-derived hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900410-2

7 January 2021

Recombinant versus plasma-derived hepatitis B vaccines: issues of safety, immunogenicity and cost-effectiveness

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900410-2

7 January 2021

Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900410-2

7 January 2021

Response to hepatitis B vaccine: multiple HLA genes are involved

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900410-2

7 January 2021

Molecular epidemiology of hepatitis B virus mutants

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900410-2

7 January 2021

The prevalence of surface antigen variants of hepatitis B virus in Papua New Guinea, South Africa, and Sardinia

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900410-2

7 January 2021

Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900410-2

7 January 2021

Immunogenicity of two recombinant hepatitis B vaccines in older individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900410-2

7 January 2021

Response to an extra dose of hepatitis B vaccine and specific antibody persistence in non-responders to primary immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900410-2

7 January 2021

Hepatitis A in Western Austria--the epidemiological situation before the introduction of active immunisation

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900410-2

7 January 2021

Two different dosages of yeast derived recombinant hepatitis B vaccines: a comparison of immunogenicity.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900410-2

7 January 2021

Comparison of immunogenicity of two yeast-derived recombinant hepatitis B vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900410-2

7 January 2021

Comparative study of the immunogenicity and safety of Engerix-B administered at 0, 1, 2 and 12 months and Recombivax HB administered at 0, 1, and 6 months in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900410-2

7 January 2021

Comparative immunogenicity under field conditions of two recombinant hepatitis B vaccines in 8-10-year-old children

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900410-2

7 January 2021

Are booster immunisations needed for lifelong hepatitis B immunity?

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900410-2

7 January 2021

Costimulatory mechanisms in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900410-2

7 January 2021

In vitro senescence models for human T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900410-2

7 January 2021

Primary and secondary alterations of immune reactivity in the elderly: impact of dietary factors and disease

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900410-2

7 January 2021

Vaccinating elderly people. Protecting from avoidable disease

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900410-2

7 January 2021

Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900410-2

7 January 2021

Hepatitis B vaccine responsiveness in Connecticut public safety personnel

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900410-2

7 January 2021

Persistence of antibodies after immunization with a recombinant yeast-derived hepatitis B vaccine following two different schedules

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900410-2

7 January 2021

Immunologic Prevention of Human Hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900410-2

7 January 2021

Persistence of antibodies following vaccination with a yeast-derived recombinant hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900410-2

7 January 2021

Long term efficacy of hepatitis B vaccine in infants born to hepatitis B e antigen-positive mothers

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900410-2

7 January 2021

A hepatitis B vaccine formulated with a novel adjuvant system

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900410-2

7 January 2021

Quantification of hepatitis B vaccine-induced antibodies as a predictor of anti-HBs persistence.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900410-2

7 January 2021

Long-term persistence of anti-HBs after vaccination with a recombinant DNA yeast-derived hepatitis B vaccine: 8-year results

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900410-2

7 January 2021

The clinical efficacy of trivalent oral polio vaccine in The Gambia by season of vaccine administration

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900410-2

7 January 2021

10.1016/S0264-410X(00)00410-2

Identifiers

DOI

1 reference

11 September 2017

1 reference